Overview The Dario Health (DRIO) story is one we have been covering since late 2019. Our team first recognized the company as a potential multibagger after speaking with the CEO at the 2020 Annual … [Read more...] about Dario Health (DRIO): Foundation Is Set for Explosive Growth In 2022
Reports
Gritstone Bio (GRTS) Leads the Pack in Vaccine-Based Immunotherapy
Overview Over the past 15 years there has been increasing interest in leveraging the immune system to fight cancer and infectious diseases. Leading treatment modalities pursued by drug developers has … [Read more...] about Gritstone Bio (GRTS) Leads the Pack in Vaccine-Based Immunotherapy
Immunogen Enters a Pivotal Year in 2022
Immunogen (ticker: IMGN) is a mid-cap clinical stage biotechnology company that is entering a critical phase of its existence. They will be presenting at the JP Morgan Conference on January 12, 2022 … [Read more...] about Immunogen Enters a Pivotal Year in 2022
Two Companies to Watch Monday at JP Morgan Healthcare Conference
Every turn of the new year, biotechnology investors look to the Annual JP Morgan HealthCare Conference. Traditionally this event has taken place in San Francisco, however again this year, the … [Read more...] about Two Companies to Watch Monday at JP Morgan Healthcare Conference
Time For T cells: Gritstone Bio (GRTS)
Situation Snapshot A new COVID-19 variant (Omicron) was recently identified in South Africa. On 11/26/21 the World Health Organization classified Omicron as a variant of concern (VOC). The decision … [Read more...] about Time For T cells: Gritstone Bio (GRTS)
Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
On 11/11/21 one of our core positions Gritstone Bio (GRTS) reported highly anticipated data from its CORAL COVID-19 vaccine program in non-human primates (NHPs). After scrupulous review and comparison … [Read more...] about Gritstone Bio Reports Promising Preclinical Data in NHPs; Efficacy Threshold Exceeded at Low Doses
BCRX Q3 Results & Discussion
BCRX Q3 Performance and Discussion*For a copy of Q3 earnings transcript, click here. To be directed to BCRX full page with reports and more, click here. Robust Orladeyo Launch Continues; Blockbuster … [Read more...] about BCRX Q3 Results & Discussion
Nonalcoholic Steatohepatitis (NASH) and its Implication on Life
What Are the Treatment options for Nonalcoholic Steatohepatitis - NASH? There is no specific treatment, but what the doctor may suggest are a few lifestyle changes that will prevent NASH … [Read more...] about Nonalcoholic Steatohepatitis (NASH) and its Implication on Life
Why We Dont Like Aurinia At $3B
Co authored by Zion MillerIntroduction: In response to recent backlash over bearish remarks on popular companies, we have decided to frame our stance in concise articles, starting with Aurina … [Read more...] about Why We Dont Like Aurinia At $3B
Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
As mentioned in our last report, Gritstone Bio (GRTS) initially applied its next-generation heterologous (virus/sa-mRNA) vaccine technology to fight cancer. The thesis articulated by the founding … [Read more...] about Gritstone Bio (GRTS) Makes History in a Historically Hopeless Setting
You must be logged in to post a comment.